Journal article

Health-Related Quality of Life and Functional Outcomes from a Randomized-Withdrawal Study of Long-Term Lisdexamfetamine Dimesylate Treatment in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder

Tobias Banaschewski, Mats Johnson, Michel Lecendreux, Alessandro Zuddas, Ben Adeyi, Paul Hodgkins, Liza A Squires, David R Coghill

CNS DRUGS | ADIS INT LTD | Published : 2014


Funding Acknowledgements

This study was funded by Shire Development LLC. Shire develops and markets drugs to treat psychiatric disorders, including ADHD.The following authors have received compensation for serving as consultants or speakers, or they, or the institutions they work for, have received research support or royalties from the companies or organizations indicated: T. Banaschewski (Hexal, Lilly, Medice, Novartis, Otsuka, Oxford Outcomes, PCM Scientific, Shire and Vifor Pharma); M. Lecendreux (Shire, UCB and Vifor Pharma); M. Johnson (Janssen, Lilly, Otsuka, PCM Scientific, Shire, Vifor Pharma, and WM Lundgrens Research Fund); A. Zuddas (AstraZeneca, Bristol-Myers Squibb/Otsuka, Lilly, Lundbeck, Shire and Vifor Pharma); D. Coghill (Flynn, Janssen-Cilag, Lilly, Medice, Novartis, Otsuka, Oxford University Press, Pfizer, Schering-Plough, Shire, UCB and Vifor Pharma). B. Adeyi and L. A. Squires are employees of Shire, and may hold Shire stock and/or stock options. P. Hodgkins is a current employee of Vertex Pharmaceuticals and a former employee of Shire.